

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 49/00, C07D 487/22 G01N 21/76	A1	(11) International Publication Number: WO 94/08631 (43) International Publication Date: 28 April 1994 (28.04.94)
(21) International Application Number: PCT/US93/10048 (22) International Filing Date: 20 October 1993 (20.10.93) (30) Priority data: 07/966,136 22 October 1992 (22.10.92) US (71) Applicant: ARIZONA BOARD OF REGENTS [US/US]; Tempe, AZ 85287 (US). (72) Inventors: GUST, John, D., Jr. ; 621 East Grace Drive, Tempe, AZ 85281 (US). MOORE, Ana, L. ; MOORE, Thomas, A. ; 5721 East Edgemont, Scottsdale, AZ 85257 (US). JORI, Giulio ; Via Cavalleri 18, I-35100 Padova (IT). REDDI, Elena ; Viale 3 Martiri 63/0, I-35100 Rov- igo (IT).		(74) Agent: MYBECK, Richard, R.; 8010 East Morgan Trail, Suite 10, Scottsdale, AZ 85258 (US). (81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: THE USE OF CAROTENOPORPHYRINS AS TUMOR LOCALIZING AGENTS FOR DIAGNOSIS, VISUALI- ZATION AND DELIVERY OF SENSITIZERS TO TUMOR TISSUES (57) Abstract A process of tumor identification comprising administering a carotenoporphyrin to a tumor-bearing mammalian host and irradiating the mammalian host with light whereupon the carotenoporphyrin, which has been preferentially taken up by the tumor tissue, fluoresces and permits precise identification of the location, size and shape of the tumor tissue. An improved process of synthesizing carotenoporphyrins 1-5 is also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

THE USE OF CAROTENOPORPHYRINS
AS TUMOR LOCALIZING AGENTS FOR
DIAGNOSIS, VISUALIZATION AND DELIVERY OF
SENSITIZERS TO TUMOR TISSUES

5

Background of the Invention

Field of the Invention

10 The present invention relates to a method of
diagnosing mammalian tumors and more particularly to a
photoidentification method of diagnosing tumor tissue using
a synthetic carotenoporphyrin which consists of a
15 carotenoid polyene covalently linked to a porphyrin or
related cyclic tetrapyrrole. The diagnostic agents
preferentially localize in tumor tissue and fluoresce upon
exposure to light. An improved method of synthesizing the
diagnostic agents employed herein is also provided.

Prior Art

20 Carotenoid pigments, ubiquitous in photosynthetic
membranes, are essential for the survival of green plants.
Two facets of carotenoid function are recognized in
photosynthetic membranes. First, carotenoids photoprotect
by rapidly quenching chlorophyll triplet states which are
25 formed in antenna systems or photosynthetic reaction
centers. This triplet-triplet energy transfer prevents
chlorophyll-photosensitized formation of highly destructive
singlet oxygen which is injurious to the organism. In
addition, carotenoids act as antennas by absorbing light in
30 spectral regions where chlorophyll absorbs weakly and
delivering the resulting excitation to chlorophyll via a
singlet-singlet energy transfer process. Finally, nearby
carotenoids quench chlorophyll first excited singlet
states. This quenching has been ascribed to energy
35 transfer or electron transfer or some other process leading
to internal conversion and is believed to play a role in
the regulation of photosynthesis.

A number of porphyrin materials have been found to localize in tumor tissue and to damage that tissue upon irradiation with light. Many of these are being investigated as therapeutic agents ("hematoporphyrin derivative" and related materials). All of these agents suffer from the problem that they are also absorbed by healthy tissue which is also harmed by the light.

Various synthetic carotenoids designed to mimic carotenoid photoprotection have been investigated by researchers at Arizona State University. Synthetic carotenoporphyrins consisting of a carotenoid part covalently linked to a synthetic meso-tetraarylporphyrin which successfully exhibited both the photophysical functions of carotenoids in photosynthesis were first reported by Gary Dirks, Ana L. Moore, Thomas A. Moore and Devens Gust in Photochemistry and Photobiology, Vol. 32, pp 277-280 (Permagon Press Ltd. Great Britain, 1980).

A carotenoporphyrin which demonstrated quenching of the porphyrin triplet state by the attached carotenoid via triplet-triplet energy transfer was reported by R.V. Bensasson, E.J. Land, A.L. Moore, R.L. Crouch, G. Dirks, T.A. Moore and D. Gust in Nature, Vol. 290, No. 5804, pp 329-332, March 16, 1981.

Since that time, various compounds which exhibit the triplet-triplet energy transfer described in Nature, supra, have been reported by the Arizona State University group.



In 1984, carotenoporphyrins 1-5 were prepared by Dr. Paul Liddell at Arizona State University and reported in his doctoral thesis dated December, 1985. Carotenoporphyrins 1-3 were reported by Harry A. Frank, Barry W. Chadwick, Jung Jin Oh, Devens Gust et al., Biochemical et Biophysical Acta 892 (1987) 253-263.


It has now been discovered that certain synthetic carotenoporphyrins preferentially localize in mammalian tumor tissue where they absorb and emit light when

irradiated with light so that the site of the tumor may be detected by the fluorescence of the localized carotenoporphyrin. Localization of the carotenoporphyrins employed in the practice of the present invention is better than that of porphyrins alone and most importantly, photodamage of tissue is precluded by the quenching of the porphyrin triplet state. Thus the present invention overcomes the problem inherent with the existing porphyrin photosensitizing compounds as diagnostic agents, that of collateral tissue damage. In fact, with the prior art porphyrins, the entire body of the mammalian host becomes photosensitive, and exposure of any body parts to light must be avoided for from several weeks to months after treatment.

Summary of the Invention

The present invention provides a method of locating and visualizing mammalian tumor tissue comprising administering a diagnostically effective amount of a carotenoporphyrin 1-5 represented by the formula:





to a mammalian host, permitting the diagnostic agent to localize in the tumor tissue and thereafter irradiating the mammalian host with light whereby the localized carotenoporphyrin fluoresces sharply defining the tumor. Light emitted from the tumor by fluorescence of the localized diagnostic agent employed in this invention sharply defines the location of the tumor to be removed or otherwise treated.

Generally speaking, the diagnostic agents of the present invention were effectively administered to representative mammals in dosages of from 0.5 to 50 mg/kg of host body weight, preferably from 3 to 48 hours prior to the diagnostic procedure or surgery.

The diagnostic agents employed in the practice of the present invention have a number of advantages over current contrast agents and tumor diagnostic procedures. Their primary advantage is a lack of toxicity. Many individuals are sensitive to present contrast agents employed, for example in computer assisted tomography (CAT) scans and there have been cases of severe allergy reactions resulting in anaphylactic shock. For these sensitive individuals, nuclear scans are often employed. However, nuclear scans require the administration of radioactive diagnostic materials and further, are useful primarily to define function as opposed to structure. Magnetic resonance imaging does not require the use of a contrast diagnostic agent and while accurate and definitive for the diagnosis of brain and other abnormalities, is expensive, unpleasantly noisy, confining for claustrophobic

individuals, and wholly unsuitable for use as an adjunct to surgery where it is desirable for the surgeon to be able to concurrently pinpoint the exact tumor location and follow his progress in excising it without damaging surrounding tissue or organs. Lower cost is an additional advantage of the present method.



The present invention also provides an improved, more convenient and economical synthesis of the diagnostic agents employed herein. Generally speaking, the porphyrin moieties were prepared by condensation of pyrrole and an appropriate mixture of aromatic aldehydes in propionic acid. The requisite carotenoid polyenes were prepared from 8'-apo- β -carotenal by means of a Wittig reaction and linked to the porphyrin via an acid chloride.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

In the examples reported below, the ^1H NMR spectra were obtained at 300 to 500 MHz and used $\leq 1\%$ solutions in chloroform- d with tetramethylsilane as an internal reference. The UV-vis spectra were recorded on a HEWLETT PACKARD 8450A spectrophotometer. For transient absorption studies, samples were placed in 1 cm x 1 cm x 4 cm cuvettes and deoxygenated by bubbling with argon. The apparatus used for the transient absorption work features excitation with ca. 15 ns pulses of less than 1 mJ at 590 nm. An adequate signal-to-noise ratio was achieved by signal averaging (typically about 500 flashes). The details of the spectrometer are described by Gust et al. J. Am. Chem. Soc. 1986, 108, 8028, incorporated by reference herein. Fluorescence decay measurements were made on ca. 1×10^{-5} M solutions using the time-correlated single photon counting method. The excitation source was a frequency-doubled, mode-locked Nd-YAG laser coupled to a synchronously pumped, cavity dumped dye laser with excitation at 590 nm. Detection was via a microchannel plate photomultiplier

(Hamamatsu R2809U-01), and the instrument response time was ca. 35 ps.

In one embodiment of this invention, a method of administering a carotenoporphyrin that will preferentially localize in tumor tissue and absorb and emit light without damaging the mammalian host upon irradiation with light comprises the steps of administering a diagnostically effective amount of a carotenoporphyrin represented by the formula:



5 allowing said carotenoporphyrin to circulate and accumulate
and localize in tumor tissue, preferably from about 3 to 48
hours prior to the diagnostic or surgical procedure, and
exposing the mammalian host to light whereby said
carotenoporphyrin fluoresces thereby permitting
10 visualization and definition of the tumor tissue to be
removed or treated.

More specifically, the carotenoporphyrin diagnostic
agent employed in the practice of this invention localizes
in tumor tissue, absorbs light of one wavelength, emits
15 light of another wavelength by porphyrin fluorescence but
does not damage healthy tissue. The process of this
invention may be used both for diagnosis and as a valuable
adjunct to surgery as light emitted from the tumor by
fluorescence of the localized porphyrin in the
20 carotenoporphyrin would sharply define the location of the
tumor tissue to be removed.

In practice, a carotenoporphyrin of Formula I is
administered intravenously to a mammalian host in a dosage
of from 0.50 to 50 mg/kg (0.42 to 42 μ mol/kg) of body
25 weight from 3 to 48 hours prior to exposure to radiation
having a wavelength of from about 300 to about 650
nanometers. The carotenoporphyrins may be conveniently
administered either solubilized in an emulsion such as a
CREMOPHOR EL emulsion (Sigma Chemical Company) or other
30 suitable fatty emulsion or incorporated into liposomes
such as unilamellar liposomes of a synthetic lipid such as
dipalmitoylphosphatidylcholine ("DPPC") sold by Sigma
Chemical Company, Inc. After the photosensitive diagnostic
agent has had sufficient time to circulate and localize in
35 tumor tissue, the mammalian host is exposed to a light

whereby the carotenoporphyrin localized in tumor tissue fluoresces permitting visualization of the tumor location, size and configuration. Suitable light sources are those that emit radiation at wavelengths of between 300 to about 650 nanometers. The porphyrins have their strongest absorption bands at about 420, 518, 550 and 650 nanometers. Thus monochromatic radiation at these wavelengths would be preferentially absorbed. In addition to using the human eye as a detector, a light-sensitive electronic device such as a photomultiplier or photodiode array could be used as a detector to provide a picture or electronic image of localized material.

The present invention is quite suitable for visualization of mammalian tumors but may require additional work for effectual visualization of hepatic or splenic tumors because of the observed propensity of the selected carotenoporphyrins to localize in the liver and spleen of the host and thereby mask the results.

To further assist in the understanding of the present invention and not by way of limitation, the following examples are presented.

Example 1

5-(-3-Aminophenyl)-10,15,20-tris(4-methylphenyl)porphyrin

To a 1-L flask equipped with a mechanical stirrer, condenser, and an addition funnel were added 300 mL of propionic acid, 22.54 g (0.188 mol) of p-tolualdehyde, and 11.3 g (0.075 mol) of m-nitrobenzaldehyde. The pale yellow solution was brought to reflux, and 16.77 g (0.25 mol) of pyrrole was added as rapidly as possible, without causing any overheating. Refluxing was continued for an additional 40 min. After cooling, the mixture was filtered, and the solid porphyrin mixture was washed with cold methanol until the filtrate was free of brown tar. After the remaining solid was dried, it (5.0 g) was dissolved in 150 mL of

concentrated hydrochloric acid to which was added 10 g of stannous chloride dihydrate. The resulting green suspension was allowed to react for 40 min at 70° C, cooled, and treated with concentrated aqueous ammonia until a pH of 8 was obtained. The solution was then extracted several times with chloroform, and the combined organic extracts were washed with three 300-mL portions of 10% aqueous ammonia and then two 400-mL portions of water. The solution containing the mixture of aminoporphyrins was dried over sodium sulfate. In order to simplify the purification process, the mixture of porphyrins was converted to the N-acetyl form. The mixture was first dissolved in a solution of 400 mL of chloroform, 30 mL of pyridine, and 20 mL of acetic anhydride and allowed to stir at room temperature under a nitrogen atmosphere for 7h. The solvent was then evaporated at reduced pressure, and residual pyridine and acetic anhydride were removed by azeotropic distillation with a 200-mL portion of toluene. The residue was dissolved in chloroform and washed with aqueous citric acid and aqueous sodium bicarbonate, and the solution was dried with sodium sulfate. Evaporation of the solvent at reduced pressure gave a purple solid, which was purified by column chromatography (silica gel/chloroform containing up to 2% acetone). The desired N-acetylporphyrin was collected, dissolved in chloroform, and refluxed for 30 min with 0.8 g of 2,3-dichloro-5,6-dicyanobenzoquinone to remove chlorins. After cooling, the solution was passed through a short bed of alumina to remove excess and reduced quinone. The eluate was evaporated to dryness at reduced pressure, and the residue was treated with 250 mL of concentrated hydrochloric acid for 19 h at 80° C to hydrolyze the amide functionality. The green reaction mixture was cooled and neutralized with aqueous sodium hydroxide, and the reddish product was extracted with dichloromethane and recrystallized from

dichloromethane/ methanol to give 1.18 g of the desired porphyrin (2.8% yield): ^1H NMR (300 MHz, CDCl_3) δ -2.78 (2 H, s, pyrrole NH), 2.69 (9H, s, tolyl CH_3), 7.04-7.63 (4 H, m, 5 ArH), 7.54 (6 H, d, J = 8.0 Hz, 10,15,20 ArH), 8.09 (6 H, d, J = 8.0 Hz, 10,15,20 ArH), 8.85-8.94 (8 H, m, pyrrole H); mass spectrum (EI) m/z 671 (M^+); UV-vis (dichloromethane) λ_{max} (nm) 420, 518, 552, 592, 648.

Example 2

5-(2-Aminophenyl)-10,15,20-tris(4-methylphenyl)porphyrin

The title compound was prepared using the method of Example 1 to give a 1.6% yield of the desired porphyrin:

^1H NMR (300 MHz, CDCl_3) δ -2.74 (2 H, s, pyrrole NH), 2.70 (9H, s, tolyl CH_3), 7.09-7.90 (5 H, m, 5 ArH), 7.55 (6 H, d, J = 7.8 Hz, 10,15,20 ArH), 8.09 (6 H, d, J = 7.8 Hz, 10,15,20 ArH), 8.09 (6H, d, J = 7.8 Hz, 10,15,20 ArH), 8.86-8.88 (8 H, m, pyrrole H); mass spectrum (EI) m/z 671 (M^+); UV-vis (dichloromethane) λ_{max} (nm) 418, 516, 552, 592, 648.

Example 3

7'-Apo-7'-(4-carboxyphenyl)- β -carotene

Into a 200-mL flask outfitted with a magnetic stirring bar, a condenser and a gas inlet tube were placed 1.0 g (2.4 mmol) of 8'-apo- β -carotenal (Hoffman LaRoche), 50 mL of dimethyl sulfoxide, 1.4 g (2.9 mmol) of 4-carboxymethoxybenzyltriphenylphosphonium bromide and 0.17 g (3.1 mmol) of sodium methoxide. The suspension was heated to 80° and stirred under an argon atmosphere. After 16 hr, supplemental amounts of both reactants were added and the reaction mixture was stirred for an additional 16 h. The reaction mixture was then poured into ether (800 ml) and the organic solution was washed six times with 150-mL portions of water to remove all traces of dimethyl sulfoxide. The ether layer was dried over anhydrous magnesium sulfate, the solvent was evaporated and the residue was recrystallized from methylene chloride-methanol

to afford 1.12g (85% yield) 7'-apo-7'-(4-carbomethoxyphenyl)- β -carotene: ^1H NMR (90 MHz CDCl_3) δ 1.03 (6H, s, C16, C17), 1.10-1.80 (6H, m, C2, C3, C4), 1.72 (3H, s, C18), 1.98 (9H, s, C19, C20, C20'), 2.06 (3H, s, C19'), 6.1-7.0 (14H, m, vinyl-H), 7.05 and 8.05 (4H, AB quartet, $J=8.3\text{Hz}$, Ar-H); mass spectrum (EI) m/z 549 (M^+); UV-vis (toluene) λ_{max} (nm) 302, 376, 458, 482, 514.

A 110mg (0.2mmol) sample of 7'-apo-7'-(4-carbomethoxyphenyl)- β -carotene was dissolved in tetrahydrofuran-methanol (3:1) (16mL). To this solution was added 2mL of 10% aqueous potassium hydroxide and the mixture was stirred under an argon atmosphere for 18h. The above solution was then partitioned between chloroform and water (pH 1-2) and the aqueous layer washed with chloroform until all the carotene had been extracted. The combined chloroform extracts were dried over anhydrous sodium sulfate and filtered, and the solvent was evaporated to yield 98 mg (91%) of the title compound: ^1H NMR (90 MHz CDCl_3) δ 1.03 (6H, s, C16, C17), 1.4-2.1 (6H, m, C2, C3, C4), 1.72 (3H, s, C18), 1.99 (9H, s, C19, C20, C20'), 2.06 (3H, s, C19'), 6.0-7.0 (14H, m, vinyl-H), 7.4-8.1 (4H, AB quartet, Ar-H); mass spectrum (EI) m/z 535 (M^+); λ_{max} (nm) (methylene chloride), 302, 376, 458, 482, 514.

Example 4

Carotenoporphyrin 1

To a 50-mL flask were added 70 mg (0.01 mmol) of 7'-apo-7'-(4-carboxyphenyl)- β -carotene (Example 3), 20 mL of dry benzene, 29 μL (0.40 mmol) of thionyl chloride, and 80 μL (0.99 mmol) of dry pyridine. The initial orange suspension was rapidly converted into the acid chloride as indicated by a dark red color. After the solution was stirred for 30 min under argon, the solvent was distilled under vacuum. Benzene (40 mL) was added and evaporated to dryness under vacuum to remove excess thionyl chloride. The residue that remained was dissolved in 30 mL of dry

dichloromethane and added to a solution of 133 mg (0.198 mmol) of 5-(4-aminophenyl)-10,15,20-tris(4-methylphenyl)porphyrin which was dissolved in 60 mL of dry dichloromethane and 0.2 mL of dry pyridine. This solution was stirred under argon for 60 min and then partitioned between dichloromethane and water. The organic layer was washed twice with 70-mL portions of water, the solvent was evaporated, and the residue was dried under vacuum. Chromatography on silica gel with toluene/0.5% ethyl acetate as the solvent and subsequent recrystallization from methylene chloride/methanol gave 82 mg (53% yield) of the carotenoporphyrin 1: ¹H NMR (400 MHz, CDCl₃) δ 1.05 (6 H, s, C16,C17), 1.48 (2 H, m, C2), 1.62 (2 H, m, C3), 1.73 (3 H, s, C18), 1.99-2.04 (11 H, m, C19, C20, C20', C4), 2.09 (3 H, s, C19'), 2.71 (9 H, s, tolyl CH₃), 6.0-7.1, (14 H, m, vinyl H), 7.55 (6 H, d, J = 5.9 Hz, 10,15,20Ar3,5H), 7.61 (2 H, d, J = 6.4 Hz, C2', C4'), 7.98 (2 H, d, J = 6.4 Hz, C1', C5'), 8.03 (2 H, d, J = 6.6 Hz, 5Ar3,5H), 8.06 (6 H, d, J = 6.1 Hz, 10,15,20Ar2,6H), 8.15 (1 H, s, NH), 8.22 (2 H, d, J = 6.6 Hz, 5Ar2,6H), 8.87 (8 H, m, pyrrole H); UV-vis (dichloromethane) λ_{max} (nm) 376, 418, 480, 512, 550 (sh), 590, 648.

Example 5

25

Carotenoporphyrin 2

Carotenoporphyrin 2 was prepared following the method of Example 4 using 133 mg (0.198 mmol) 5-(3-aminophenyl)-10,15,20-tris(4-methylphenyl)porphyrin to give 79mg (51%) of product: ¹H NMR (500 MHz, CDCl₃) δ 1.04 (6 H, m, C16,C17), 1.48 (2 H, m, C2), 1.63 (2 H, m, C3), 1.73 (3 H, s, C18), 1.98 (9 H, s, C19,C20,C20'), 2.02 (3 H, s, C19'), 2.70-2.71 (9 H, m, tolyl CH₃), 6.0-7.0 (14 H, m, vinyl H), 7.44 and 7.83 (4 H, AB, C1',C5',C2',C4'), 7.55 (6 H, m, 10,15,20Ar3,5H), 8.85 (8 H, m, pyrrole H); UV-vis

(dichloromethane) λ_{\max} (nm) 373, 418, 480, 512, 550 (sh), 590, 646.

Example 6

Carotenoporphyrin 3

5 Carotenoporphyrin 3 was prepared following the procedure of Example 4 using 133 mg (0.198 mmol) of 5-(2-aminophenyl)-10,15,20-tris(4-methylphenyl)porphyrin to yield 49 mg (32%) of the desired product: ¹H NMR (500 MHz, CDCl₃) δ 1.03-1.06 (6 H, m, C16,C17), 1.48 (2 H, m, C2),
10 1.62 (2 H, m, C3), 1.72 (3 H, s, C18), 1.87 (3 H, s, C19'), 1.96-1.98 (9 H, s, C19,C20,C20'), 2.0 (2 H, m, C4), 2.70-2.72 (9 H, m, tolyl CH₃), 5.90-6.90 (14 H, m, vinyl H), 6.43 and 6.49 (4H, AB, J = 8.5 Hz, ArH), 7.50-8.20 (12 H, m, ArH), 8.80-9.10 (8 H, m, pyrrole H); UV-vis
15 (dichloromethane) λ_{\max} (nm) 373, 418, 480, 550 (sh), 590, 648.

Example 7

7'-Apo-7'-(4-aminophenyl)- β -carotene

20 To a 100-mL flask were added 0.50 g (1.2 mmol) of 8'-apo- β -carotenal, 80 mL of dimethyl sulfoxide, 1.1 g (2.4 mmol) of [4-(N-acetylamino)benzyl]triphenylphosphonium bromide and 0.20 g (3.7 mmol) of sodium methoxide. The mixture was stirred for 5 h under argon at 60-70° C and was then quenched by pouring the dark orange solution into 500
25 mL of ether and washing the resulting solution with water repeatedly in order to remove most of the dimethyl sulfoxide. The organic layer was dried over anhydrous magnesium sulfate and filtered, and the solvent was evaporated under reduced pressure. The resulting crude
30 carotenoid amide was dissolved in 30 mL of tetrahydrofuran to which 75 mL of saturated methanolic potassium hydroxide solution was added. This solution was heated to 63°C, stirred under an argon atmosphere for 5.5 h, and then poured into 500 mL of ether and washed six times with 150-
35 mL portions of water. The organic layer was dried over

anhydrous magnesium sulfate and filtered, and the solvent was evaporated. The residue was chromatographed with chloroform on a dry-packed silica gel column to give 319 mg (53% yield) of the pure aminocarotenoid: ¹H NMR (400 MHz, CDCl₃) δ 1.03 (6 H, s, C16,C17), 1.48 (2 H, m, C2), 1.61 (2 H, m, C3), 1.72 (3 H, s, C18), 1.97-1.98 (9 H, m, C19,C20,C20'), 2.0 (2 H, m, C4), 2.02 (3 H, s, C18'), 3.75 (2 H, s, NH₂), 6.11-6.76 (14H, m vinyl H), 7.25-7.28 (4 H, m, ArH); mass spectrum (EI) m/z 506 (M⁺); UV-vis (dichloromethane) λ_{max} (nm) 376, 478, 506.

Example 8

Carotenoporphyrin 4

To a 50-mL flask equipped with a condenser and nitrogen gas line were added 120 mg (0.17 mmol) of 5-(4-carboxyphenyl)-10,15,20-tris(4-methylphenyl)porphyrin (J.A. Anton et al., J. Heterocyclic Chem. 1976, 13, 717), 30 mL of dichloromethane, and 3.0 mL of oxalyl chloride. The dark green solution was refluxed under nitrogen for 1 h and cooled, and the solvent was evaporated under vacuum. Two 25-mL portions of toluene were successively added and then evaporated under vacuum in order to remove all traces of excess oxalyl chloride. The residue was dissolved in a mixture of dichloromethane (50 mL) and pyridine (1 mL). The resulting solution was added to 70 mg (0.138 mmol) of 7'-apo-7'-(4-aminophenyl)-β-carotene dissolved in 50 mL of dichloromethane and stirred under argon. After 1 h, the reaction mixture was poured into 180 mL of dichloromethane and washed twice with 100-mL portions of water. The organic layer was separated, and the solvent evaporated. Residual water and pyridine were removed by azeotropic distillation with toluene. The residue was chromatographed on silica gel (dichloromethane), and the product was recrystallized from dichloromethane/methanol to afford 76

mg (46% yield) of the pure carotenoporphyrin 4: ¹H NMR (400 MHz, CDCl₃) δ 1.03 (6 H, m, C16,C17), 1.47 (2 H, m, C2), 1.62 (2 H, m, C3), 1.72 (3 H, s, C18), 1.98-2.01 (9 H, m, C19,C20,C20'), 2.02-2.06 (2 H, m, C4'), 2.08 (3 H, s, C19'), 2.71 (9 H, s, tolyl CH₃), 6.0-7.0 (14 H, m, vinyl H), 7.52-7.60 (8 H, m, 10,15,20Ar3,5H and C2',C4'), 7.77 (2 H, d, J = 8.6 Hz, C1',C5'), 8.10 (6 H, d, J = 7.9 Hz, 10,15,20Ar2,6H), 8.14 (1 H, s, NH), 8.26 and 8.35 (4 H, AB, J = 8.2 Hz, 5ArH), 8.78-9.00 (8 H, m, pyrrole H); UV-vis (dichloromethane) λ_{max} (nm) 373, 418, 476, 510, 550 (sh), 592, 648.

Example 9

Carotenoporphyrin 5

Carotenoporphyrin 5 was prepared following the method of Example 8 from 100 mg (0.143 mmol) of 5-(2-carboxyphenyl)-10,15,20-tris(4-methylphenyl)porphyrin. (J.A. Anton et al., J. Heterocyclic Chem. 1975, 12, 573. A total of 77 mg of pure product was obtained (45% yield): ¹H NMR (400 MHz, CDCl₃) δ 1.02-1.05 (6 H, m, C16,C17), 1.47 (2 H, m, C2), 1.60 (2 H, m, C3), 1.69 (3 H, s, C18), 1.71 (3 H, s, C19') 1.86 (3 H, s, C20'), 1.95-1.97 (6 H, m, C19,C20), 2.01-2.05 (2 H, m, C4), 2.70 (9 H, s, tolyl CH₃), 5.50-6.80 (14 H, m, vinyl H), 7.03 (1 H, s, NH), 7.50-8.50 (20 H, m, Ar H), 8.77-8.91 (8 H, m, pyrrole H); UV-vis (dichloromethane) λ_{max} (nm) 372, 418, 478, 512, 550 (sh), 592, 648.

Example 10

Porphyrin 6

To a 100-mL flask were added 110 mg (0.16 mmol) of 5-(4-aminophenyl)-10,15,20-tris(4-methylphenyl)porphyrin, 40 mL of dichloromethane, and 40 μL (0.49 mmol) of pyridine. The mixture was stirred under a nitrogen atmosphere and 37 μL (0.32 mmol) of benzoyl chloride was added. The reaction was complete after 30 min. The mixture was diluted with 60 mL of dichloromethane and washed with dilute hydrochloric

acid, aqueous sodium bicarbonate and aqueous sodium chloride. The resulting organic phase was dried over anhydrous sodium sulfate and filtered, and the solvent was distilled from the filtrate under reduced pressure. The resulting purple solid was recrystallized from dichloromethane/methanol to give 115 mg (92% yield) of the desired porphyrin: ^1H NMR (300 MHz, CDCl_3) δ -2.77 (2 H, s, pyrrole NH), 2.71 (9 H, s, tolyl CH_3), 7.56 (6 H, d, J = 7.9 Hz, 10,15,20ArH), 7.60-8.07 (5 H, m, ArH), 8.05 (2 H, d, J =8.3 Hz, 5ArH), 8.10 (6 H, d, J = 7.9 Hz, 10,15,20ArH), 8.16 (1 H, s, NH), 8.24 (2 H, d, J = 8.3 Hz, 5ArH), 8.87-8.88 (8 H, m, pyrrole H); mass spectrum (EI) m/z 775 (M^+); UV-vis (dichloromethane) λ_{max} (nm) 420, 518, 554, 594, 650.

Example 11

In vivo uptake of carotenoporphyrin 1

Carotenoporphyrin 1 (5 mg/kg, 4.2 $\mu\text{mol/kg}$ body weight) solubilized in CREMOPHOR EL (castor oil and ethylene oxide) emulsion (Sigma Chemical Company, Inc.) was injected into Balb/c mice bearing a transplanted MS-2 fibrosarcoma. Carotenoporphyrin levels in serum and selected organs and tissues were measured 3, 24, 48 and 96 hours following injection by absorption and fluorescence. Carotenoporphyrin levels are set forth in Table I.

TABLE I
Carotenoporphyrin Levels ($\mu\text{g/g}$)

	Mouse Serum	Tumor	Liver	Spleen	Muscle	Skin	Time
30	1 28.97	2.69	7.65	4.01	0.26	0.43	3h
	2 32.33	2.45	7.29	3.74	0.30	0.34	
	3 26.38	3.32	7.98	4.24	0.25	0.32	
	average 29.23	2.82	7.64	4.00	0.27	0.36	
	s.d. 2.98	0.45	0.35	0.25	0.03	0.06	
35	4 1.3	4.84	22.19	11.35	0.24	0.63	24h
	5 0.93	5.82	24.77	10.76	0.39	0.84	
	6 1.23	7.85	24.77	11.66	0.41	0.62	
	average 1.18	6.17	27.48	11.16	0.35	0.70	
	s.d. 0.23	1.54	7.04	0.62	0.09	0.12	
40	7 0.12	5.62	30.42	15.75	0.39	0.92	
	8 0.13	5.11	25.27	9.94	0.33	0.66	

5	9	0.16	6.51	30.16	14.09	0.44	0.82	48h
	average	0.14	5.75	28.62	13.26	0.39	0.80	
	s.d	0.02	0.71	2.90	2.99	0.06	0.13	
	10	0.03	2.57	25.80	10.34	0.27	0.68	96h
	11	0.02	3.07	26.16	11.37	0.30	0.70	
12	0.02	2.58	26.04	7.33	0.29	0.48		
average	0.03	2.74	26.00	9.68	0.29	0.62		
s.d	0.002	0.29	0.18	2.10	0.02	0.12		

15

20

25

30

35

TABLE II
Carotenoporphyrin Levels (μ g/g)

Mouse	Serum	Tumor	Liver	Spleen	Muscle	Skin	Time
1	66.20	7.66	15.34	3.95	0.91	0.88	3h
2	60.00	6.88	14.82	3.13	1.44	1.15	
3	52.76	8.36	15.69	3.00	1.13	1.07	
average	59.65	7.63	15.28	3.36	1.16	1.03	
s.d	6.73	0.74	0.44	0.51	0.27	0.14	
4	3.05	12.65	43.59	9.61	1.02	1.54	24h
5	4.63	14.80	51.03	12.62	0.95	1.13	
6	4.32	17.40	53.65	15.63	1.53	1.98	
average	4.00	14.95	49.42	12.62	1.16	1.55	
s.d.	0.84	2.38	5.22	3.01	0.32	0.42	

35

40

45

50

55

60

65

70

75

80

85

90

95

100

105

110

115

120

125

130

135

140

145

150

155

160

165

170

175

180

185

190

195

200

205

210

215

220

225

230

235

240

245

250

255

260

265

270

275

280

285

290

295

300

305

310

315

320

325

330

335

340

345

350

355

360

365

370

375

380

385

390

395

400

405

410

415

420

425

430

435

440

445

450

455

460

465

470

475

480

485

490

495

500

505

510

515

520

525

530

535

540

545

550

555

560

565

570

575

580

585

590

595

600

605

610

615

620

625

630

635

640

645

650

655

660

665

670

675

680

685

690

695

700

705

710

715

720

725

730

735

740

745

750

755

760

765

770

775

780

785

790

795

800

805

810

815

820

825

830

835

840

845

850

855

860

865

870

875

880

885

890

895

900

905

910

915

920

925

930

935

940

945

950

955

960

965

970

975

980

985

990

995

1000

1005

1010

1015

1020

1025

1030

1035

1040

1045

1050

1055

1060

1065

1070

1075

1080

1085

1090

1095

1100

1105

1110

1115

1120

1125

1130

1135

1140

1145

1150

1155

1160

1165

1170

1175

1180

1185

1190

1195

1200

1205

1210

1215

1220

1225

1230

1235

1240

1245

1250

1255

1260

1265

1270

1275

1280

1285

1290

1295

1300

1305

1310

1315

1320

1325

1330

1335

1340

1345

1350

1355

1360

1365

1370

1375

1380

1385

1390

1395

1400

1405

1410

1415

1420

1425

1430

1435

1440

1445

1450

1455

1460

1465

1470

1475

1480

1485

1490

1495

1500

1505

1510

1515

1520

1525

1530

1535

1540

1545

1550

1555

1560

1565

1570

1575

1580

1585

1590

1595

1600

1605

1610

1615

1620

1625

1630

1635

1640

1645

1650

1655

1660

1665

1670

1675

1680

1685

1690

1695

1700

1705

1710

1715

1720

1725

1730

1735

1740

1745

1750

1755

1760

1765

1770

1775

1780

1785

1790

1795

1800

1805

1810

1815

1820

1825

1830

1835

1840

1845

1850

1855

1860

1865

1870

1875

1880

1885

1890

1895

1900

1905

1910

1915

1920

1925

1930

1935

1940

1945

1950

1955

1960

1965

1970

1975

1980

1985

1990

1995

2000

2005

2010

2015

2020

2025

2030

2035

2040

2045

2050

2055

2060

2065

2070

2075

2080

2085

2090

2095

2100

2105

2110

2115

2120

2125

2130

2135

2140

2145

2150

2155

2160

2165

2170

2175

2180

2185

2190

2195

2200

2205

2210

2215

2220

2225

2230

2235

2240

2245

2250

2255

2260

2265

2270

2275

2280

2285

2290

2295

2300

2305

2310

2315

2320

2325

2330

2335

2340

2345

2350

2355

2360

2365

2370

2375

2380

2385

2390

2395

2400

2405

2410

2415

2420

2425

2430

2435

2440

2445

2450

2455

2460

2465

2470

2475

2480

2485

2490

2495

2500

2505

2510

2515

2520

2525

2530

2535

2540

2545

2550

2555

2560

2565

2570

2575

2580

2585

2590

2595

2600

2605

2610

2615

2620

2625

2630

2635

2640

2645

2650

2655

2660

2665

2670

2675

2680

2685

2690

2695

2700

2705

2710

2715

2720

2725

2730

2735

2740

2745

2750

2755

2760

2765

2770

2775

2780

2785

2790

2795

2800

2805

2810

2815

2820

2825

2830

2835

2840

2845

2850

2855

2860

2865

2870

2875

2880

2885

2890

2895

2900

2905

2910

2915

2920

2925

2930

2935

2940

2945

2950

2955

2960

2965

2970

2975

2980

2985

2990

2995

3000

3005

3010

3015

3020

3025

3030

3035

3040

3045

3050

3055

3060

3065

3070

3075

3080

3085

3090

3095

3100

3105

3110

3115

3120

3125

3130

3135

3140

3145

3150

3155

3160

3165

3170

3175

3180

3185

3190

3195

3200

3205

3210

3215

3220

3225

3230

3235

3240

3245

3250

3255

3260

3265

3270

3275

3280

3285

3290

3295

3300

3305

3310

3315

3320

3325

3330

3335

3340

3345

3350

3355

3360

3365

3370

3375

3380

3385

3390

3395

3400

3405

3410

3415

3420

3425

3430

3435

3440

3445

3450

3455

3460

3465

3470

3475

3480

3485

3490

3495

3500

3505

3510

3515

3520

3525

3530

3535

3540

3545

3550

3555

3560

3565

3570

3575

3580

3585

3590

3595

3600

3605

3610

3615

3620

3625

3630

3635

3640

3645

3650

3655

3660

3665

3670

3675

3680

3685

3690

3695

3700

3705

3710

3715

3720

3725

3730

3735

3740

3745

3750

3755

3760

3765

3770

3775

3780

3785

3790

3795

3800

3805

3810

3815

3820

3825

3830

3835

3840

3845

3850

3855

3860

3865

3870

3875

3880

3885

3890

3895

3900

3905

3910

3915

3920

3925

3930

3935

3940

3945

3950

3955

3960

3965

3970

3975

3980

3985

3990

3995

4000

4005

4010

4015

4020

4025

4030

4035

4040

4045

4050

4055

4060

4065

4070

4075

4080

4085

4090

4095

4100

4105

4110

4115

4120

4125

4130

4135

4140

4145

4150

4155

4160

4165

4170

4175

4180

4185

4190

4195

4200

4205

4210

4215

4220

4225

4230

4235

4240

4245

4250

4255

4260

4265

4270

4275

4280

4285

4290

4295

4300

4305

4310

4315

4320

4325

4330

4335

4340

4345

4350

4355

4360

4365

4370

4375

4380

4385

4390

4395

4400

4405

4410

4415

4420

4425

4430

4435

4440

4445

4450

4455

4460

4465

4470

4475

4480

4485

4490

4495

4500

4505

4510

4515

4520

4525

4530

4535

4540

4545

4550

4555

4560

4565

4570

4575

4580

4585

4590

4595

4600

4605

4610

4615

4620

4625

4630

4635

4640

4645

4650

4655

4660

4665

4670

4675

4680

4685

4690

4695

4700

4705

4710

4715

4720

4725

4730

4735

4740

4745

4750

4755

4760

4765

4770

4775

4780

4785

4790

4795

4800

4805

4810

4815

4820

4825

4830

4835

4840

4845

4850

4855

4860

4865

4870

4875

4880

4885

4890

4895

4900

4905

4910

4915

4920

4925

4930

4935

4940

4945

4950

4955

4960

4965

4970

4975

4980

4985

4990

4995

5000

5005

5010

5015

5020

5025

5030

5035

5040

5045

5050

5055

5060

5065

5070

5075

5080

5085

5090

5095

5100

5105

5110

5115

5120

5125

5130

5135

5140

5145

5150

5155

5160

5165

5170

5175

5180

5185

5190

5195

5200

5205

5210

5215

5220

5225

5230

5235

5240

5245

5250

5255

5260

5265

5270

5275

5280

528

5	5	0.13	1.19	9.34	4.33	0	0	8h
	6	0.10	0.74	9.24	5.74	0.05	0	
	average	0.10	0.97	9.15	5.25	0.04	0	
	s.d.	0.03	0.32	0.25	0.80	0.04	0	
10	7	0.05	0.23	7.78	8.64	0.09	0.11	24h
	8	0.04	0.18	9.01	*4.47	0	0.05	
	9	0.07	0.18	9.11	8.18	0	0	
	average	0.05	0.20	8.63	8.41	0.03	0.05	
	s.d.	0.02	0.03	0.74	0.33	0.05	0.06	
15	10	0.01	0.19	6.77	6.09	0.31	0.05	48h
	11	0.02	0.28	7.94	6.08	0	0.09	
	12	0.01	0.18	7.73	4.82	0.14	0	
	average	0.01	0.22	7.48	5.66	0.15	0.05	
	s.d.	0.01	0.05	0.62	0.73	0.16	0.05	

* Not considered in averaging data

Example 14

The procedure of Example 13 was repeated using i.v. injections of 0.65 mg/kg (0.84 μ moles/kg) of body weight of the carotenoporphyrin incorporated into unilamellar liposomes of DPPC (dipalmitoylphosphatidylcholine, Sigma Chemical Company). The results are set forth in Table IV.

TABLE IV
Carotenoporphyrin Levels (μ g/g)

	Mouse	Serum	Tumor	Liver	Spleen	Muscle	Skin	Time
30	1	0.18	0.11	11.00	2.43	0.11	0.02	3h
	2	0.19	0.13	7.10	2.12	0.09	0	
	3	0.10	0.05	2.37	1.25	0.09	0.05	
	average	0.16	0.10	4.53	1.93	0.10	0.02	
	s.d.	0.05	0.04	2.39	0.61	0.01	0.02	
35	4	0.04	0.14	5.36	3.13	0.03	0.03	24h
	5	0.04	0.09	5.22	2.10	0.02	0.07	
	6	0.03	0.15	6.83	1.52	0.02	0.05	
	average	0.04	0.13	5.80	2.25	0.02	0.05	
	s.d.	0.01	0.03	0.89	0.81	0.01	0.02	

The mechanism of the carotenoporphyrins employed in the present invention generally works as follows. C-P represents a porphyrin (P) covalently attached to a carotenoid (C) by chemical bonds. In use, the following sequence occurs:

C-P is administered to a mammalian host and localizes in tumor tissue with small amounts deposited in other tissues and larger amounts deposited in the spleen and liver. The tissue is irradiated with light (hv) and some is absorbed by the porphyrin producing the porphyrin first excited single state, C-¹P, according to the following reaction sequence:



Some of the porphyrin singlet states emit light of a different wavelength (fluoresce) (hv') and this is detected by the surgeon or physician. This sequence is represented as follows:



Some of the porphyrin singlet states undergo intersystem crossing to form the triplet state of the porphyrin, C-³P as follows:



Before the porphyrin triplet state can react with oxygen or other molecules to initiate tissue damage, the carotenoid quenches it by energy transfer:





The carotenoid triplet state ³C-P is harmless and decays to the normal ground state C-P without doing any damage and is eventually excreted by the host organism.

From the foregoing, it is readily apparent that a useful embodiment of the present invention has been herein described and illustrated which fulfills all of the aforestated objectives in a remarkably unexpected fashion. It is of course understood that such modifications, alterations and adaptations as may readily occur to the artisan confronted with this disclosure are intended within the spirit of this disclosure which is limited only by the scope of the claims appended hereto.

Accordingly, what is claimed is:

1. A method of locating a diagnostic agent in and visualizing non-hepatic and non-splenic mammalian tumor tissue in a mammalian host comprising: administering to a mammalian host an effective amount of a carotenoporphyrin represented by the formula:



permitting said carotenoporphyrin to localize in the tumor tissue; and thereafter exposing said mammalian host to light whereby said carotenoporphyrin fluoresces permitting precise visualization of the tumor location, size and shape.

2. The method of claim 1 wherein said carotenoporphyrin is administered intravenously prior to initiation of a diagnostic or surgical procedure.

5 3. The method of claim 2 wherein said carotenoporphyrin is administered intravenously as a solubilized emulsion.

10 4. The method of claim 2 wherein said carotenoporphyrin is incorporated into liposomes prior to administration.

15 5. The method of claim 1 wherein said carotenoporphyrin is carotenoporphyrin 1.

6. The method of claim 1 wherein said carotenoporphyrin is carotenoporphyrin 2.

20 7. The method of claim 1 wherein said carotenoporphyrin is carotenoporphyrin 3.

8. The method of claim 1 wherein said carotenoporphyrin is carotenoporphyrin 4.

25 9. The method of claim 1 wherein said carotenoporphyrin is carotenoporphyrin 5.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/10048

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61K 49/00; C07D 487/22; G01N 21/76

US CL : 424/7.1; 436/172, 800; 540/145

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/7.1; 436/172, 800; 540/145

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN (Chemical Abstracts Registry File)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF PHYSICAL CHEMISTRY, Volume 91, Issued 1987, E. J. Land et al., "Pulse Radiolytic and Electrochemical Investigations of Intramolecular Electron Transfer in Carotenoporphyrins and Carotenoporphyrin-Quinone Triads", pages 4831-4835.	1-9
A	US, A, 5,015,463 (Dougherty et al.) 14 May 1991, see column 1, lines 37-62 and claim 1.	1-9
A	US, A, 5,149,708 (Dolphin et al.) 22 September 1992, see abstract.	1-9
A	US, A, 4,806,488 (Berger, Jr. et al.) 21 February 1989, see abstract	1-9



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)	g	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

28 December 1993

Date of mailing of the international search report

04 FEB 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

GARY E. HOLLINDEN

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)*

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.